Cosciens Biopharma Inc. · TSX:CSCI
Cosciens Biopharma — Aeterna Zentaris — Investor Presentation (January 2022)
30 slides from Cosciens Biopharma's investor presentation, Jan 26, 2022
Slide 1: In Pursuit of Medical Innovations: Corporate Presentation
zentaris.com NASDAQ: AEZS / TSX: AEZS Exhibit 99.2 ALTERNA ZENTARIS In Pursuit of Medical Innovations January 2022 Corporate Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements This document contains forward looking statements (as defined by applicable securities legislation) made pursuant to the safe harbor provision of the US Securities Litigation Reform Act of 1995 and forward-looking information (as defined under applicable Canadian securitie
Slide 3: Investment highlights
Diversified portfolio focused on areas Leveraging network of large pharmaceutical of significant unmet medical need and university partners and collaborators Executing strategy to deliver multiple Strong financial position with runway development and regulatory milestones expected to fund operations
Slide 4: Diagnostic Development Pipeline and Commercial Rights
Diagnostic Commercial and Development Pipeline Commercial Rights Program Indication Preclinical Phase 1 Phase2 Phase3 Commercial U.S./Canada Europe Israel ROW g | | | Sag xs) - Adult Growth Hormone AX Gensilient NegaPharni) ETERNA Fg Maino ce TT @ ACER | OZENTARIS 2 — | D Childhood-Onset Growth is B
Slide 5: Therapeutic and Vaccine Development Pipeline
Therapeutic and Vaccine Development Pipeline Program Indication Preclinical Phase1 Phase2 Phase3 ———————— Program Highlights Neuromyelitis Optica Spectrum Disorder || In-licensed program in January 2021 merece 2 AIM Biologicals (NMOSD) UNIVERSITAT = Parkinson's Disease || In-licensed program in Sept
Slide 6: Development Programs
Development Programs Advancing Therapeutics and Vaccines to Secure Long-Term Growth ETERNA 6 ZENTARIS
Slide 7: Technology platform enabling highly specific treatment for auto-immune diseases
Technology platform enabling highly specific treatment for auto-immune diseases with well-defined target antigens Maternal Blood and a Modulation of immune response towards auto- antigens by induction of antigen-specific regulatory T cells and by elimination of cognate antigen- specific cytotoxic T
Slide 8: The Promise of Targeted, Physiological, Antigen-Specific Immunomodulation
The Promise of Targeted, Physiological, Antigen-Specific Immunomodulation * mS © ‘ AIM Biologics Autoimmune Immunosuppressive Antigen-specific Diseases Therapeutics Immunomodulation Enhanced by autoreactive Reduce disease symptoms Various antigens may be used for effector T cells : highly selective
Slide 9: AIM Biologicals Concept
AIM Biologicals Concept’ * Adaptable platform of immunomodulating molecules * Soluble fusion proteins eycecxoualiialem-mOeptide (= antigen)mMallean is coupled to the proteins via a |inker ¢ The proteins interacts with the target cells via the T-cell receptor (TCR) and ILT-2 to induce immune toleranc
Slide 10: Antigen-Specific Immunomodulation for NMOSD and Parkinson's
The Promise of Targeted, Physiological, Antigen-Specific Immunomodulation Potential selective treatment option for Potential treatment option for Parkinson's <> neuromyelitis optica spectrum disorder disease (PD) (NMOSD) @ Well-defined antigen: Aquaporin-4 (AQP4) S a-Synuclein (a-Syn) described as t
Slide 11: AEZS-150: Delayed Clearance Parathyroid Hormone Fusion Polypeptide
AEZS-150: Delayed Clearance Parathyroid Hormone (DC-PTH) Fusion Polypeptide Hypoparathyroidism Body produces abnormally low levels of PTH Orphan indication © ~23-37 re 100,000° ts ~~ on PTH is a key regulating hormone Ny) essential for calcium homeostasis and renal phosphate clearance ro) + O Potent
Slide 12: AEZS-150: Fusion Polypeptide Pharmacokinetics
1 AEZS-150: Delayed Clearance Parathyroid Hormone (DC-PTH) Fusion Polypeptide AEZS-150: Fusion-Protein of PTH [1-34] coupled via a linker Plasma Pharmacokinetics in a Rat Study? to a modified growth-hormone binding protein (GHBP)' 18 3 PTHU1-34] nM] 2° & DC-PTH [nM] 15: Delayed clearance in comparis
Slide 13: Salmonella-based oral vaccine platform
Potential for temperature stable supply chain: ~2°C - 8°C! Live-attenuated bacterial vaccine based on the Salmonella typhi Ty21a carrier strain currently used as a typhoid vaccine Potential to induce systemic and mucosal immunity to prevent infection systemic gLinmniyiso This new, alternative and un
Slide 14: Pre-clinical oral coronavirus vaccine
Currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including CC) i) COVID-19 (SARS-CoV-2) intone Modified Salmonella typhi Ty21a SARS-CoV-2 antigens a: aa 2 pats ¥ Adaptable Plasmid Vector Induction of Immunity Multiple-Antigens Potential to induce mucosal Higher l
Slide 15: Development Plan Towards Phase 1: Oral Coronavirus Vaccine
Development Plan Towards Phase 1 Oral Coronavirus Vaccine Fue2023: Planned start of clinical development for oral vaccine Pre-clinical safety and toxicology assessment Manufacturing process assessment / development Virus challenge experiments in immunized transgenic animals In-vivo immunology experi
Slide 16: Chlamydia trachomatis vaccine
16 Sexually transmitted gram-negative bacterium infecting over 130 million subjects annually Whereas symptomatic infection can be treated by antibiotics, asymptomatic disease can spread to the reproductive tract inducing infertility, miscarriage, or ectopic pregnancy, which is a life-threatening con
Slide 17: University of Queensland collaboration
THE UNIVERSITY ¥ OF QUEENSLAND | AUSTRALIA i! VY Exclusive rights for AEZS to Investigation as a potential University researchers to negotiate a license agreement for the treatment for Amyotrophic Lateral Sclerosis (ALS, Lou secure grants and conduct commercial use of the results Gehrig's disease) p
Slide 18: The Science Behind Macimorelin in ALS
The Science Behind Macimorelin in ALS Importance of Ghrelin and the GH/IGF-1 axes in ALS! = Ghrelin is a natural endogenous hormone that stimulates appetite and lowers metabolic rate to promote weight gain = Ghrelin also regulates the release of the neuroprotective and anabolic hormones growth hormo
Slide 19: The Science Behind Macimorelin in ALS
The Science Behind Macimorelin in ALS Macimorelin is a Ghrelin mimetic and modulates various disease-relevant processes Macimorelin Disease modifiers (Ghrelin mimetic) (& pathophysiology) t Next Steps: Direct/indirect neuroprotection Motor neuron death ‘2 Proof of concept with macimorelin in Anti-in
Slide 20: Roadmap for Advancing Development Programs Towards IND Filing
Roadmap for Advancing Development Programs Towards IND Filing _ Clinical Pre-clinical Development a =e Development Establish Experimental Establish Transfer joint pre- work in-vitro Select Formalized clinical FDA Initiate of program clinical and in-vivo development pre-clinical development _ pre-IND
Slide 21: Macimorelin / Macrilen: Oral Diagnostic Test for Growth Hormone Deficiency
2a Macimorelin / Macrilen™ A Disruptive Oral Diagnostic Test Solution for Growth Hormone Deficiency First and only AGHD test approved by US FDA and European Commission ALTERNA ZENTARIS
Slide 22: Growth hormone produced by the pituitary gland
Produced by the pituitary gland (located at the base of the brain)
Slide 23: No Other FDA or EC Approved Oral Test
No Other FDA or EC Approved Oral Test Insulin tolerance test (ITT) considered ‘ITT Test] is increasingly used less the “Gold Standard” in GHD detection frequently in the U.S. because of procedures’? safety concerns.” 2 Not FDA or EC approved or regulated 2: AACE 2019 Guidelines: American Association
Slide 24: Pediatric GHD Phase 3 study design
Children and adolescents from 2 to less than 18 years of age with if suspected GHD to be enrolled 2 (Years) <18 Open-label, single dose, multicenter, multinational US, Czech Republic, Germany, Poland, Georgia, Italy, : 2 100 subjects worldwide Serbia, Romania, Russia, Slovenia and Ukraine ; Macimore
Slide 25: Macimorelin Commercial Rights
Macimorelin Commercial Rights Actively seeking commercial partners in ROW novo nordisk License and Assignment Agreement Territories: United States and Canada Royalties on sales Sales milestones Aeterna Zentaris controls API supply chain and provides API Co-development for expansion into CGHD + Novo
Slide 26: Corporate Overview
Corporate Overview ETERNA 26 SPETERNA wn
Slide 27: Cash on Hand, Market Cap, Shares Outstanding
Cash on Hand Market Cap’ Shares 3 month As of September 30, Outstanding’ Avg. Volume* 2021 |and outstanding AEZS shares on that date
Slide 28: Management team
Giuliano La { e Nicola Ammer, MD am § Michael Teifel, PhD Fratta Y f SVP Clinical SVP Non-Clinical SVP Finance, " Development, Development, Chief Financial ss Chief Medical Officer ’ Chief Scientific Officer Officer 3
Slide 29: Footnotes
1: Based on Management's current expectations and planned development activities
Slide 30: Investor & Media Relations
zentaris.com NASDAQ: AEZS / TSX: AEZS ALTERNA ZENTARIS In Pursuit of Medical Innovations Investor & Media Relations JTC Team 833.475.8247 aezs@jtcir.com
Aeterna Zentaris — Investor Presentation (January 2022) on 6ix